Bio Techne Corp (TECH):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Bio Techne Corp (TECH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10115
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Bio Techne Corp (Bio Techne), formerly Techne, develops, produces, and markets biotechnology products and scientific tools to understand biological processes and drive research. The company’s portfolio encompasses native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization. It offers Western blot, enzyme-linked immunosorbent assay, and biologics platform. Bio Techne also offers controls and calibrators for hematology clinical instruments. Bio Techne’s products find application in scientific investigation of biological processes and also to identify the nature and progress of certain diseases. The company sells its products through an extensive network of distributors across the world. It caters to biotechnology research and clinical diagnostic markets. The company has subsidiaries in the UK, Canada, and China. Bio Techne is headquartered in Minneapolis, Minnesota, the US.

Bio Techne Corp (TECH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Bio Techne Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bio Techne Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bio Techne Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bio Techne Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bio Techne Corp, Medical Devices Deals, 2012 to YTD 2018 10
Bio Techne Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Bio Techne Corp, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Quad Technologies Raises Funds through Series A Financing 13
Zephyrus Biosciences Raises USD1.5 Million in Seed Financing 14
Partnerships 15
Exosome Diagnostics Enters into Agreement with Intezyne 15
Quad Technologies Enters into Partnership with Sartorius Stedim Biotech 16
COPD Foundation Enters into Agreement with Bio Techne 17
Quad Technologies Partners with University of Massachusetts Medical School 18
Indica Labs Enters into Co-Marketing Agreement with Advanced Cell Diagnostics 19
MicroMatrices Associates Enters into Co-Development Agreement with Advanced Cell Diagnostics 20
Life Technologies Enters Into Distribution Agreement With Advanced Cell Diagnostics 21
Licensing Agreements 22
Bio-Techne Enters into Licensing Agreement with MRC for Protein Synthesis Technology 22
Equity Offering 23
Astute Medical Raises USD43 Million in Private Palcement of Shares 23
ProteinSimple Withdraws IPO 24
ChemoCentryx Completes Private Placement Of Shares For US$5 Million 25
Acquisition 26
Bio-Techne to Acquire Quad Technologies 26
Bio Techne Acquires Atlanta Biological 27
Bio Techne Acquires Trevigen 28
Bio-Techne Acquires Zephyrus Biosciences 29
Bio-Techne Acquires Cyvek 30
Bio-Techne Completes Acquisition of ProteinSimple for USD308 Million 31
Bio-Techne Acquires Novus Biologicals for USD60 Million 33
Bio-Techne Acquires Shanghai PrimeGene Bio-Tech 34
Novus Biologicals Acquires Imgenex, Biotech Company 35
Bio Techne Corp – Key Competitors 36
Bio Techne Corp – Key Employees 37
Bio Techne Corp – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 40
Financial Announcements 40
Oct 30, 2018: Bio-Techne releases first quarter fiscal 2019 results 40
Aug 07, 2018: Bio-Techne releases fourth quarter fiscal 2018 results 43
May 02, 2018: Bio-Techne Releases Third Quarter Fiscal 2018 Results 46
Feb 06, 2018: Bio-Techne Reports Net Sales Of $154.2 million In The Second Quarter Of Fiscal 2018 48
Oct 31, 2017: Bio-Techne Releases First Quarter Fiscal 2018 Results 50
Aug 08, 2017: Bio-Techne Releases Fourth Quarter Fiscal 2017 Results 52
Feb 07, 2017: Bio-Techne Releases Second Quarter Fiscal 2017 Results 55
Corporate Communications 57
Oct 26, 2017: Bio-Techne Adds Two New Directors to Its Board 57
Product News 58
Mar 14, 2018: Bio-Techne Launches MimEX GI, an Accessible 3-D Cell Culturing Platform for the Gastrointestinal Tract 58
Other Significant Developments 59
Jul 24, 2018: Bio-Techne introduces new member of the Simple Western Family, with IR/NIR detection capabilities 59
Jul 10, 2018: Bio-Techne Scales Antibody Validation Initiative Using CRISPR Gene Editing Technology Across a Broad Spectrum of Targets 60
Apr 26, 2018: Bio-Techne Leads the Way in Scientific Support for Autophagy Research 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Bio Techne Corp, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Bio Techne Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bio Techne Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Bio Techne Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bio Techne Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Bio Techne Corp, Medical Devices Deals, 2012 to YTD 2018 10
Bio Techne Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Quad Technologies Raises Funds through Series A Financing 13
Zephyrus Biosciences Raises USD1.5 Million in Seed Financing 14
Exosome Diagnostics Enters into Agreement with Intezyne 15
Quad Technologies Enters into Partnership with Sartorius Stedim Biotech 16
COPD Foundation Enters into Agreement with Bio Techne 17
Quad Technologies Partners with University of Massachusetts Medical School 18
Indica Labs Enters into Co-Marketing Agreement with Advanced Cell Diagnostics 19
MicroMatrices Associates Enters into Co-Development Agreement with Advanced Cell Diagnostics 20
Life Technologies Enters Into Distribution Agreement With Advanced Cell Diagnostics 21
Bio-Techne Enters into Licensing Agreement with MRC for Protein Synthesis Technology 22
Astute Medical Raises USD43 Million in Private Palcement of Shares 23
ProteinSimple Withdraws IPO 24
ChemoCentryx Completes Private Placement Of Shares For US$5 Million 25
Bio-Techne to Acquire Quad Technologies 26
Bio Techne Acquires Atlanta Biological 27
Bio Techne Acquires Trevigen 28
Bio-Techne Acquires Zephyrus Biosciences 29
Bio-Techne Acquires Cyvek 30
Bio-Techne Completes Acquisition of ProteinSimple for USD308 Million 31
Bio-Techne Acquires Novus Biologicals for USD60 Million 33
Bio-Techne Acquires Shanghai PrimeGene Bio-Tech 34
Novus Biologicals Acquires Imgenex, Biotech Company 35
Bio Techne Corp, Key Competitors 36
Bio Techne Corp, Key Employees 37
Bio Techne Corp, Subsidiaries 38

List of Figures
Bio Techne Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bio Techne Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bio Techne Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bio Techne Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bio Techne Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Bio Techne Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Bio Techne Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Bio Techne Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Bio Techne Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Bio Techne Corp (TECH):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Avon Rubber Plc (AVON):企業の財務・戦略的SWOT分析
    Avon Rubber Plc (AVON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Cryo-Cell International Inc (CCEL):企業の財務・戦略的SWOT分析
    Summary Cryo-Cell International Inc (Cryo-Cell) operates as a cord blood bank service provider. The company offers biotechnology services, collection and preservation of umbilical cord blood stem cells for family use. It provides services such as cord blood banking, cord tissue banking, cord blood a …
  • Pets at Home Group Plc (PETS):企業の財務・戦略的SWOT分析
    Pets at Home Group Plc (PETS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Energoprojekt Holding AD (ENHL):企業の財務・戦略的SWOT分析
    Energoprojekt Holding AD (ENHL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Thermo Fisher Scientific Inc (TMO):医療機器:M&Aディール及び事業提携情報
    Summary Thermo Fisher Scientific Inc (Thermo Fisher) is a provider of equipment, analytical instruments, reagents and consumables, software and services to tackle complex analytical challenges in research, diagnostics and clinical laboratories. It offers solutions for cellular analysis and biology, …
  • Sika Interplant Systems Limited
    Sika Interplant Systems Limited - Strategy, SWOT and Corporate Finance Report Summary Sika Interplant Systems Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Maruti Suzuki India Limited:企業の戦略・SWOT・財務分析
    Maruti Suzuki India Limited - Strategy, SWOT and Corporate Finance Report Summary Maruti Suzuki India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • IntegraGen SA (ALINT):医療機器:M&Aディール及び事業提携情報
    Summary IntegraGen SA (IntegraGen) is a developer and commercializer of molecular diagnostic tests for the treatment of autism and oncology. The company provides advanced genomic and bioinformatic services, including clinical research, basic and human genetic research, bioinformatics and bioanalysis …
  • Mineral Resources Ltd:企業の戦略・SWOT・財務分析
    Mineral Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Mineral Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Tidewater Inc (TDW):企業の財務・戦略的SWOT分析
    Summary Tidewater Inc (Tidewater) is an an petroleum service company that offers offshore supply vessels and marine support services. The company's services include transport and supply of offshore material; anchor handling, towing and positioning; construction support; well stimulation, FPSO suppor …
  • London North West Healthcare NHS Trust:企業の戦略的SWOT分析
    London North West Healthcare NHS Trust - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • Egyptian General Petroleum Corporation:石油・ガス:M&Aディール及び事業提携情報
    Summary Egyptian General Petroleum Corporation (EGPC), formerly General Petroleum Authority, is engaged in the oil and gas exploration services. The company is engaged in the refining, production, drilling, transportation and storage of crude oil; production of lubricants and greases; provides man p …
  • Luminex Corp (LMNX)-製薬・医療分野:企業M&A・提携分析
    Summary Luminex Corp (Luminex) is a medical devices company which develops, manufactures and markets proprietary biological testing technologies. The company offers wide range of products including instruments, assays, reagents and accessories, software and replacement parts. Its proprietary technol …
  • Straumann Holding AG (STMN):企業の財務・戦略的SWOT分析
    Straumann Holding AG (STMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • China Resources Power Holdings Co Ltd:企業の発電所・SWOT分析2018
    China Resources Power Holdings Co Ltd - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informatio …
  • Wellcome Trust Sanger Institute-製薬・医療分野:企業M&A・提携分析
    Summary Wellcome Trust Sanger Institute (Sanger Institute), a subsidiary of Genome Research Ltd is a genomic discovery and research centre that carries out research and development in the areas of cellular and human genetics and infection genomics. It also provides postgraduate training on research …
  • Aon plc:戦略・SWOT・企業財務分析
    Aon plc - Strategy, SWOT and Corporate Finance Report Summary Aon plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • RTI Surgical Inc (RTIX):企業の財務・戦略的SWOT分析
    Summary RTI Surgical Inc (RTI), formerly RTI Biologics Inc is a surgical implant company that offers biologic, metal and synthetic implants. The company’s products include spine implants, surgical specialties, sports medicine implants, cardiothoracic and orthobiologics. It offers spine implants such …
  • Reata Pharmaceuticals Inc (RETA):企業の財務・戦略的SWOT分析
    Summary Reata Pharmaceuticals Inc (Reata) is a clinical-stage biopharmaceutical company that develops innovative medicines for the treatment of serious and life-threatening diseases. The company’s clinical candidates include bardoxolone methyl and omaveloxolone, which target Nrf2, a transcription fa …
  • WNDM Medical Inc (WNDM):医療機器:M&Aディール及び事業提携情報
    Summary WNDM Medical Inc (WNDM Medical), formerly Wound Management Technologies Inc is a distributor of biotechnology products to hospitals, physicians, and clinics. The company offers its patented product CellerateRX in powder and gel forms, and hemaquell resorbable bone wax that controls bone blee …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆